Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom.
Department of Health Science and Technology, ETH Zurich, Basel, Switzerland; Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland.
Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1163-1173. doi: 10.1016/j.ijrobp.2023.07.002. Epub 2023 Jul 16.
Rectal dose delivered during prostate radiation therapy is associated with gastrointestinal toxicity. Treatment plans are commonly optimized using rectal dose-volume constraints, often whole-rectum relative-volumes (%). We investigated whether improved rectal contouring, use of absolute-volumes (cc), or rectal truncation might improve toxicity prediction.
Patients from the CHHiP trial (receiving 74 Gy/37 fractions [Fr] vs 60 Gy/20 Fr vs 57 Gy/19 Fr) were included if radiation therapy plans were available (2350/3216 patients), plus toxicity data for relevant analyses (2170/3216 patients). Whole solid rectum relative-volumes (%) dose-volume-histogram (DVH), as submitted by treating center (original contour), was assumed standard-of-care. Three investigational rectal DVHs were generated: (1) reviewed contour per CHHiP protocol; (2) original contour absolute volumes (cc); and (3) truncated original contour (2 versions; ±0 and ±2 cm from planning target volume [PTV]). Dose levels of interest (V30, 40, 50, 60, 70, 74 Gy) in 74 Gy arm were converted by equivalent-dose-in-2 Gy-Fr (EQD2) for 60 Gy/57 Gy arms. Bootstrapped logistic models predicting late toxicities (frequency G1+/G2+, bleeding G1+/G2+, proctitis G1+/G2+, sphincter control G1+, stricture/ulcer G1+) were compared by area-undercurve (AUC) between standard of care and the 3 investigational rectal definitions.
The alternative dose/volume parameters were compared with the original relative-volume (%) DVH of the whole rectal contour, itself fitted as a weak predictor of toxicity (AUC range, 0.57-0.65 across the 8 toxicity measures). There were no significant differences in toxicity prediction for: (1) original versus reviewed rectal contours (AUCs, 0.57-0.66; P = .21-.98); (2) relative- versus absolute-volumes (AUCs, 0.56-0.63; P = .07-.91); and (3) whole-rectum versus truncation at PTV ± 2 cm (AUCs, 0.57-0.65; P = .05-.99) or PTV ± 0 cm (AUCs, 0.57-0.66; P = .27-.98).
We used whole-rectum relative-volume DVH, submitted by the treating center, as the standard-of-care dosimetric predictor for rectal toxicity. There were no statistically significant differences in prediction performance when using central rectal contour review, with the use of absolute-volume dosimetry, or with rectal truncation relative to PTV. Whole-rectum relative-volumes were not improved upon for toxicity prediction and should remain standard-of-care.
在前列腺放射治疗期间,直肠的剂量与胃肠道毒性有关。治疗计划通常使用直肠剂量-体积限制来优化,通常使用整个直肠的相对体积(%)。我们研究了改进直肠轮廓、使用绝对体积(cc)或直肠截断是否可以改善毒性预测。
如果有放射治疗计划(2350/3216 例患者),并且有相关分析的毒性数据(2170/3216 例患者),则将参加 CHHiP 试验的患者纳入研究。按照 CHHiP 方案审查的整个实体直肠相对体积(%)剂量-体积直方图(DVH),假设为标准护理。生成了三个研究性直肠 DVH:(1)根据 CHHiP 协议审查的轮廓;(2)原始轮廓的绝对体积(cc);和(3)截断的原始轮廓(2 个版本;距计划靶区[PTV] ± 0 和 ± 2 cm)。在 74 Gy 臂中,将 74 Gy 臂中感兴趣的剂量水平(V30、40、50、60、70、74 Gy)转换为 60 Gy/57 Gy 臂的等效剂量-2 Gy-Fr(EQD2)。通过标准护理与 3 种研究性直肠定义之间的曲线下面积(AUC),比较了预测迟发性毒性(频率 G1+/G2+、出血 G1+/G2+、直肠炎 G1+/G2+、括约肌控制 G1+、狭窄/溃疡 G1+)的概率模型。
与整个直肠轮廓的原始相对体积(%)DVH 相比,替代剂量/体积参数的预测毒性能力较差(8 种毒性测量指标的 AUC 范围为 0.57-0.65)。原始与审查后的直肠轮廓(AUCs,0.57-0.66;P=0.21-0.98)、相对体积与绝对体积(AUCs,0.56-0.63;P=0.07-0.91)以及整个直肠与 PTV 周围 ± 2 cm(AUCs,0.57-0.65;P=0.05-0.99)或 PTV 周围 ± 0 cm(AUCs,0.57-0.66;P=0.27-0.98)的截断之间,毒性预测没有显著差异。
我们使用由治疗中心提交的整个直肠相对体积 DVH 作为直肠毒性的标准护理剂量预测指标。在使用中央直肠轮廓审查、使用绝对体积剂量学或与 PTV 周围直肠截断进行预测时,没有统计学上的显著差异。直肠相对体积的改进并未改善毒性预测,因此仍应作为标准护理。